Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”), have until Monday, May 4, 2026 to seek appointment as lead plaintiff of the Boston Scientific class action lawsuit. Captioned Troike v.
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Boston Scientific Corporation (NYSE: BSX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Boston Scientific securities between July 23, 2025 and February 3, 2026, both dates inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Boston Scientific To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Boston Scientific Corporation (NYSE: BSX - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-five research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on
New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, for each share of Penumbra that they own. KSF is seeki.
NEW YORK, April 7, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Boston Scientific Corporation (NYSE: BSX) between July 23, 2025 and February 3, 2026, inclusive (the "Class Period"), of the important May 4, 2026 lead plaintiff deadline. So what: If you purchased Boston Scientific common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
In the most recent trading session, Boston Scientific (BSX) closed at $61.86, indicating a -1.17% shift from the previous trading day.
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
